Loading...
ASCO Lung Cancer 20192025-01-27T17:44:02+01:00

ASCO 2019 – Chicago

Lecture Board: Rafał Dziadziuszko, MD, PhD; Enriqueta Felip, MD, PhD; Maximilian Hochmair, MD; Sanjay Popat, PhD, FRCP;
Elisabeth Quoix, MD
Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ASCO 2019

memo_InOncology_Special_ASCO_2019_Eng

Full report (english)

memo_InOncology_Special_ASCO_2019_Mandarin

Full report (mandarin)

memo_InOncology_Special_ASCO_2019_japanese

Full report (japanese)

EXPERT VIDEOS

All video interviews from ASCO 2019

Martin Reck gives an overview on where we are today regarding immunotherapies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.

Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.

Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.

Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.

In the area of target therapies, novel agents as well as combinations of established drugs will most likely define new standards for patients with advanced NSCLC in the years to come. (ASCO 2019)

Elisabeth Quoix • MD, Dep. of Pneumology, Hopitaux Universitaires de Strasbourg
Go to Top